Europa Worldwide Group Enhances Carbon Management and Reporting With Blue Yonder
28.8.2025 10:00:00 EEST | Business Wire | Press release
The global regulatory landscape, particularly in the U.K. and European Union, acts as a powerful catalyst for change, urging companies to embrace sustainable practices that extend beyond basic compliance. Logistics service providers (LSPs) are witnessing an increased demand from their customers to actively monitor emissions and ensure adherence to both current and forthcoming regulations. That’s why Europa Worldwide Group, a leading LSP with a global presence, has adopted Blue Yonder’s Logistics Emissions Calculator, part of the Sustainable Supply Chain Manager solution, to meet its sustainability goals and evolving customer demands.
Europa Worldwide, celebrated for its cutting-edge logistics solutions, has integrated Blue Yonder’s advanced logistics carbon management capabilities—recently enhanced by the acquisition of Pledge—across its Road Freight division in the U.K., Ireland, Belgium, and the Netherlands. This strategic implementation underscores the company's commitment to offering sustainable logistics services.
Europa Worldwide selected Blue Yonder for its ability to deliver precise and detailed carbon emissions reports, leveraging millions of data points through advanced emissions modelling. Blue Yonder’s Logistics Emissions Calculator provides GLEC-accredited and ISO 14083-aligned calculations, ensuring industry-recognized accuracy and credibility. Furthermore, Blue Yonder’s seamless API integration with Europa Worldwide’s transportation management system facilitates efficient carbon reporting, enhancing transparency and customer trust.
Prior to adopting Blue Yonder, Europa Worldwide faced challenges with its in-house emissions reporting method, which lacked the granularity and accreditation necessary for impactful sustainability efforts. The limitations of the previous system highlighted the need for a more robust solution to meet customer demands for precise data and to support the global initiative towards Net Zero.
“Europa Worldwide is proactively advancing towards more defined sustainability objectives,” said Tom Jenkins, Central Services Director, Europa Worldwide Group. “Since implementing Blue Yonder’s Logistics Emissions Calculator, we have experienced a significant rise in customer engagement with emissions reporting, showcasing the solution's value. The integration of Blue Yonder’s emission reporting capabilities underscores our dedication to maximizing strategic efforts in enhancing sustainability within logistics.”
The new reporting system was first launched in Europa Worldwide’s Road department, receiving significant usage by customers, with up to four new customers being added per week. Europa Worldwide plans to extend Blue Yonder’s Logistics Emissions Calculator to its Air and Sea customers by the end of 2025, further integrating emissions reporting into its customer self-serve portal for enhanced accessibility and self-service.
“Amidst a global push for sustainable practices, Europa Worldwide seized the opportunity to be a leader in addressing carbon emissions from logistics,” said Saskia Van Gendt, chief sustainability officer, Blue Yonder. “By strategically embedding sustainability into their operations, they are not only improving visibility for carbon emissions but also future proofing their business and their customers’ business against regulatory shifts. We are proud to support their journey towards decarbonizing transportation.”
Additional Resources:
- Learn more about Blue Yonder’s solutions for Logistics Service Providers
About Europa Worldwide Group
Europa Worldwide Group is an ambitious independent logistics operator with three divisions, Europa Road, Europa Air & Sea dedicated to getting goods from A to B on time, and Europa Warehouse, 3PL and warehousing experts who store, pack and dispatch goods for our customers. The group employs over 1,300 people globally with sites across the UK and Ireland, plus Europa’s own teams in Belgium, the Netherlands, France, Czech Republic, Hong Kong, China, India, the UAE and South Africa. The global operator has an annual turnover of £300m+. europa-worldwide.com
About Blue Yonder
Blue Yonder is the AI company for supply chain. As the world leader in end-to-end digital supply chain transformation, Blue Yonder offers a unified, AI-driven platform and multi-tier network that empowers businesses to operate sustainably, scale profitably, and delight their customers—all at machine speed. A pioneer in applying AI solutions to the most complicated supply chain challenges, Blue Yonder’s modern innovations and unmatched industry expertise help more than 3,000 retailers, manufacturers, and logistics service providers confidently navigate supply chain complexity and disruption. blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250828837213/en/
Contacts
Blue Yonder Public Relations Contacts
mediarelationsteam@blueyonder.com
U.S.: +1 480-308-3037
EMEA: +39 335 7849149
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom